Trials / Completed
CompletedNCT02881346
Efficacy and Tolerability of Enstilar® in Daily Practice
Prospective, Observational, Non-interventional, Multicenter Study on the Efficacy and Tolerability of Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in Patients With Plaque Psoriasis Under Daily Practice Conditions
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 410 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to assess how the Enstilar® aerosol foam performs in daily real-life practice with regards to effectiveness and convenience of application to psoriasis plaques on body and extremities. In addition the profiles of patients prescribed Enstilar® will be described, and preceeding, concomitant and follow-up management will be mapped. The study will be conducted in about 100 dermatology clinics all over Germany,
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enstilar® | Once daily application of cutaneous foam to plaques on body and/or extremities |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2017-03-01
- Completion
- 2017-03-01
- First posted
- 2016-08-29
- Last updated
- 2019-12-13
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02881346. Inclusion in this directory is not an endorsement.